Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYRO3 | Q06418 | 1/20 | 0.32 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30134238 | 0.71 | ATAD2 (0.30) | — | |
| SCHEMBL19153397 | 0.68 | KDM4E (0.41) | — | |
| SCHEMBL30375316 | 0.67 | EGFR (0.33) | — | |
| SCHEMBL25462861 | 0.67 | PDK2 (0.39) | — | |
| SCHEMBL1270307 | 0.67 | EGFR (0.33) | — | |
| SCHEMBL29486398 | 0.65 | DAO (0.56) | — | |
| SCHEMBL29486393 | 0.65 | DAO (0.56) | — | |
| SCHEMBL747250 | 0.65 | DAO (0.56) | — | |
| SCHEMBL8208498 | 0.65 | — | — | |
| SCHEMBL31210501 | 0.64 | MAPK1 (0.36) | TYRO3DYRK1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2367431-B1 | ORGANIC COMPOUNDS | INTRA CELLULAR THERAPIES INC (US) | 2015-08-05 | — | — | EP | disclosed |
| US-20140315868-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2014-10-23 | — | — | US | disclosed |
| US-20140315868-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2014-10-23 | — | — | US | disclosed |
| US-8697710-B2 | Optionally substituted 3-amino-4-(thioxo or imino)-4,5-dihydro-2H-pyrazolo [3,4-d]pyrimidin-6(7H)-ones | INTRA-CELLULAR THERAPIES, INC. (US) | 2014-04-15 | — | — | US | disclosed |
| US-8697710-B2 | Optionally substituted 3-amino-4-(thioxo or imino)-4,5-dihydro-2H-pyrazolo [3,4-d]pyrimidin-6(7H)-ones | INTRA-CELLULAR THERAPIES, INC. (US) | 2014-04-15 | — | — | US | disclosed |
| US-20120094966-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. | 2012-04-19 | — | — | US | disclosed |
| US-20120094966-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. | 2012-04-19 | — | — | US | disclosed |
| CN-102223799-A | Organic compounds | INTRA CELLULAR THERAPIES INC | 2011-10-19 | — | — | CN | disclosed |
| EP-2367431-A1 | ORGANIC COMPOUNDS | Intra-Cellular Therapies, Inc. (US) | 2011-09-28 | — | — | EP | disclosed |
| EP-2367431-A1 | ORGANIC COMPOUNDS | Intra-Cellular Therapies, Inc. (US) | 2011-09-28 | — | — | EP | disclosed |
| WO-2010065153-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315868-A1 | ORGANIC COMPOUNDS | TPMT, CYP4X1, P2RX4 | TYRO3 319/4885DYRK1B 3446/4885 |
| US-20120094966-A1 | ORGANIC COMPOUNDS | TPMT, CYP4X1, P2RX4 | TYRO3 319/4885DYRK1B 3446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.